I work in the Policy and Campaigns team at Breast Cancer Now.
Trastuzumab deruxtecan (also known as Enhertu) which is already available on the NHS for certain patients with secondary (metastatic) HER2 positive breast cancer is now being assessed for treating HER2-low unresectable or secondary breast cancer after chemotherapy.
This is the first time a treatment is being assessed for HER2-low. Broadly speaking, HER2-low re-defines the classification of HER2 negative into: HER2-low which refers to tumours with an IHC score of 1+ or 2+ without HER2 gene amplification and HER2-negative with an IHC score of 0.
If you have received trastuzumab deruxtecan for HER2-low secondary breast cancer, for example, through the clinical trial or privately, we want to hear from you to inform our work on this treatment.
The assessment of this treatment for use on the NHS in England by the National Institute of Health and Care Excellence (NICE) has just started and we expect a decision in autumn 2023.
If you'd be happy to share your experience, please get in touch with firstname.lastname@example.org Any views shared with us would be used anonymously.